Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Multiple Myeloma 8Neoplasms 7Nausea 7Leukemia 7Lymphoma, Non-Hodgkin 5Lymphoma 5Immunoglobulin Light-chain Amyloidosis 4Breast Neoplasms 4Polycystic Ovary Syndrome 3Lymphoma, Follicular 3Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Sarcoma 2Prostatic Neoplasms 2Primary Myelofibrosis 2Postoperative Nausea and Vomiting 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Ovarian Neoplasms 2Obesity 2Neuroblastoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Hearing Tests 1Dexamethasone 1Cisplatin 1Audiometry 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Ototoxicity × Dexamethasone × Clear all
NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ohio State University Comprehensive Cancer Center

Phase NA Withdrawn

Ototoxicity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡